← Human Trials & Peer-Reviewed Studies
Selective sodium-dependent glucose transporter 1 inhibitors block glucose absorption and impair glucose-dependent insulinotropic peptide release
Plain-language guide to PMID 25767259 (2015): placebo-controlled randomized controlled trial study of GIP (Gastric Inhibitory Polypeptide) in 12 subjects.
Key Facts
- PMID
- 25767259
- Journal
- American journal of physiology. Gastrointestinal and liver physiology
- Year
- 2015
- Study type
- Randomized Controlled Trial
- Authors
- Dobbins RL et al. (9 authors)
- DOI
- 10.1152/ajpgi.00286.2014
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of GIP (Gastric Inhibitory Polypeptide), published as a randomized controlled trial.
SGLT1 inhibitor effects on plasma glucose, insulin, gastric inhibitory peptide (GIP), and glucagon-like peptide-1 (GLP-1) concentrations were also measured during a standard meal.
Minimal effects were observed in the secretion of the L cell product, GLP-1.
Who Took Part
The abstract describes 12 subjects taking part.
By PubMed's age tags, the people studied were adults and middle-aged adults, both men and women.
How the Study Was Run
The researchers set it up as a randomized, placebo-controlled and crossover study.
The subjects were allocated by chance, so the GIP (Gastric Inhibitory Polypeptide) group and the comparison group should start out alike.
A placebo (an inactive look-alike) gave the GIP (Gastric Inhibitory Polypeptide) group a baseline to be compared against.
In the crossover set-up each of the subjects took both GIP (Gastric Inhibitory Polypeptide) and the comparison in turn, acting as their own control.
Tracer absorption and distribution were assessed from plasma, urine, and fecal samples.
What Was Measured
SGLT1 inhibitor effects on plasma glucose, insulin, gastric inhibitory peptide (GIP), and glucagon-like peptide-1 (GLP-1) concentrations were also measured during a standard meal.
The subject headings attached to it are 3-O-Methylglucose, Biological Availability, Drug Monitoring, Gastric Inhibitory Polypeptide, Glucagon-Like Peptide 1, Glucose and Glucosides.
Author keywords: KGA-2727, clinical trial and gastric inhibitory peptide.
What This Means in Plain Language
The paper is a randomized, placebo-controlled and crossover study of GIP (Gastric Inhibitory Polypeptide) in 12 subjects.
With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.
The publication is from 2015 (American journal of physiology. Gastrointestinal and liver physiology), a journal based in United States.
More context: the GIP (Gastric Inhibitory Polypeptide) compound page, all human trials.
Our Notes on the Compound
GIP (Gastric Inhibitory Polypeptide): A 42-amino-acid gut hormone that boosts insulin release after meals; one of the two receptors tirzepatide acts on.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.